New Risk • May 17
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$22m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$22m free cash flow). Negative equity (-US$13m). Minor Risks Shareholders have been diluted in the past year (28% increase in shares outstanding). Revenue is less than US$5m (US$1.1m revenue). Market cap is less than US$100m (US$33.9m market cap). Reported Earnings • May 17
Third quarter 2026 earnings released: US$0.55 loss per share (vs US$0.94 loss in 3Q 2025) Third quarter 2026 results: US$0.55 loss per share (improved from US$0.94 loss in 3Q 2025). Net loss: US$5.55m (loss narrowed 9.7% from 3Q 2025). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Aankondiging • Apr 24
Pluri Inc., Annual General Meeting, Jun 15, 2026 Pluri Inc., Annual General Meeting, Jun 15, 2026. Location: at matam advanced technology park building no. 5, haifa, Israel Aankondiging • Mar 27
Pluri Inc. announced that it expects to receive $2.5 million in funding Pluri Inc. announced that it has Securities Purchase Agreement relates to a private placement offering consisting of: 625,000 common shares, par value $0.00001 per share of the Company, and warrants to purchase up to 625,000 common shares of the Company at an issue price of $4 per share for gross proceeds of 2,500,000 on March 26, 2026. The warrants are exercisable immediately upon closing of the transaction at an exercise price of $4.25 per share and will be exercisable until the expiration of the eighteen-month anniversary of the closing of the transaction. The offer and sale of the foregoing securities is being made in a private placement in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder, or applicable state securities laws. Accordingly, the securities offered in the private placement may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The warrants are exercisable immediately upon closing of the transaction at an exercise price of $4.25 per share and will be exercisable until the expiration of the eighteen-month anniversary of the closing of the transaction. Reported Earnings • Feb 15
Second quarter 2026 earnings released: US$0.71 loss per share (vs US$0.53 loss in 2Q 2025) Second quarter 2026 results: US$0.71 loss per share (further deteriorated from US$0.53 loss in 2Q 2025). Net loss: US$6.54m (loss widened 121% from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. Aankondiging • Jan 23
Pluri Inc. Receives Notice of Non-Compliance with Nasdaq Listing Standards On January 20, 2026, Pluri Inc. (the Company") received a written notice (the Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq") indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(2), which requires the Company to maintain a minimum of $35 million in market value of listed securities (MVLS") for continued listing on The Nasdaq Capital Market (the MVLS Requirement"), nor is it in compliance with either of the alternative listing standards, including having stockholders' equity of at least $2.5 million or net income of $500,000 from continuing operations in the most recently completed fiscal year, or in two of the three most recently completed fiscal years. The Notice has no immediate effect on the listing or trading of the Company's common shares, which will continue to trade on The Nasdaq Capital Market under the symbol PLUR". Pursuant to the Notice, and in accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has been provided with an initial period of 180 calendar days, until July 20, 2026, to regain compliance with the MVLS Requirement (the Compliance Period"). Nasdaq indicated that if, at any time during the Compliance Period, the Company's MVLS closes at $35 million or more for a minimum of 10 consecutive business days (unless Nasdaq, in its discretion, requires a longer period, but generally no more than 20 consecutive business days), Nasdaq will provide a written confirmation that the Company has regained compliance and the matter will be closed. In the event the Company does not regain compliance within the Compliance Period, the Company expects that Nasdaq will provide written notification that the Company's securities are subject to delisting. At that time, the Company may be eligible to appeal any delisting determination to a Nasdaq Hearings Panel. The hearing request would stay any suspension or delisting action pending the conclusion of the hearing process and the expiration of any additional extension period granted by the panel following the hearing. The Company is evaluating options to regain compliance with the MVLS Requirement and intends to take appropriate actions to regain compliance; however, there can be no assurance that the Company will be able to regain compliance with all applicable requirements or maintain compliance thereafter. Aankondiging • Jan 22
Pluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich Biomaterials Pluri Inc. announced the completion of the first phase of its program with Resbiomed Technologies OOD ("Resbiomed"), a European biotechnology company developing extracellular-matrix-based biomaterials and biologics for regenerative medicine. The program is being executed through Pluri's contract development and manufacturing division, PluriCDMO. In June 2025, Pluri Biotech Ltd., a wholly owned subsidiary of the Company, and a provider of Contract Development and Manufacturing ("CDMO") services under its PluriCDMO business line, entered into an agreement with Resbiomed to apply Pluri's proprietary placenta-derived processing and bioprocessing capabilities to enhance, standardize and enable scalable production of placenta-derived biomaterials containing naturally occurring human collagen. Pluri believes scalable, standardized manufacturing of placenta-derived collagen-rich materials can expand access across regenerative medicine, advanced wound care, medical devices, 3D cell culture and bioprinting, and selected aesthetics. For Pluri, it views the agreement as underscoring growing demand for PluriCDMO services among companies developing next-generation, cell- and tissue-based technologies, and further strengthens PluriCDMO's position as a partner for biologics and advanced biomaterials programs requiring reproducibility, scale, and robust manufacturing controls. Aankondiging • Dec 10
Pluri Inc. announced that it expects to receive $2.5 million in funding from Chutzpah Holdings Limited Pluri Inc. announced that it has entered into a Securities Purchase Agreement for a private placement offering of 625,000 common shares, par value $0.00001 per share at a price of $4.00 for gross proceeds of $2,500,000 and will issue Common Warrants to purchase up to 625,000 Common Shares on December 8, 2025. The transaction includes participation from Chutzpah Holdings LP a limited partnership beneficially owned by Mr. Alexandre Weinstein, a non-U.S. investor and an existing shareholder and director of the Company. The Common Warrants will be exercisable immediately at an exercise price of $4.25 per share and will be exercisable until June 30, 2026. The Common Warrants contain customary anti-dilution provisions and are subject to a 35% beneficial ownership limitation. The Securities Purchase Agreement contains customary representations, warranties and indemnification obligations of the parties. The Offering is expected to close on or about December 15, 2025, subject to the satisfaction of customary closing conditions. The securities issued with respect to the Offering are exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Section 4(a)(2) of the Securities Act and/or Rule 903 of Regulation S promulgated thereunder. The securities have not been registered under the Securities Act and may not be sold in the United States absent registration or an exemption from registration. The offer and sale of the foregoing securities is being made in a private placement in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder, or applicable state securities laws. Accordingly, the securities offered in the private placement may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Aankondiging • Dec 09
Pluri Inc. Announces Chairman of the Board of Directors Changes Pluri Inc. announced that Mr. Alejandro Weinstein, one of the Company’s largest shareholders, has been appointed Chairman of the Board of Directors. The appointment reflects the Board’s view that Mr. Weinstein brings a decisive, business driven perspective that aligns with Pluri’s objectives of strengthening market positioning and accelerating the recognition and realization of the significant value embedded in the Company’s underlying assets. Mr. Weinstein, a prominent investor, has built and scaled global companies across healthcare, biotechnology, and wellness, including transforming CFR Pharmaceuticals into a multinational group later acquired by Abbott for $2.9 billion, and founding leading investment platforms such as WM Partners, Olive Tree Ventures, and Vanterra Ventures, which is active in functional food and nutrition innovation. His proven ability to grow companies, execute strategic transactions, and lead value driven organizations makes him a strong candidate to serve as Chairman. As part of this leadership evolution, Mr. Zami Aberman, who has served as Pluri’s Chairman for two decades, will transition into the role of Vice Chairman and continue to support the Company’s strategic direction. Reported Earnings • Nov 14
First quarter 2026 earnings released: US$0.65 loss per share (vs US$1.08 loss in 1Q 2025) First quarter 2026 results: US$0.65 loss per share (improved from US$1.08 loss in 1Q 2025). Net loss: US$5.85m (flat on 1Q 2025). Revenue is forecast to grow 111% p.a. on average during the next 2 years, compared to a 22% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Board Change • Oct 01
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 3 experienced directors. 2 highly experienced directors. Independent Chairman Zami Aberman is the most experienced director on the board, commencing their role in 2005. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Sep 18
Full year 2025 earnings released: US$3.56 loss per share (vs US$3.99 loss in FY 2024) Full year 2025 results: US$3.56 loss per share. Net loss: US$22.6m (loss widened 8.1% from FY 2024). Revenue is forecast to grow 94% p.a. on average during the next 2 years, compared to a 20% growth forecast for the Biotechs industry in the US. New Risk • Sep 18
New major risk - Negative shareholders equity The company has negative equity. Total equity: -US$865k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$865k). Shareholders have been substantially diluted in the past year (44% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Revenue is less than US$5m (US$1.3m revenue). Market cap is less than US$100m (US$37.0m market cap). New Risk • Jun 26
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Shareholders have been substantially diluted in the past year (47% increase in shares outstanding). Minor Risks Significant insider selling over the past 3 months (US$69k sold). Revenue is less than US$5m (US$1.0m revenue). Market cap is less than US$100m (US$34.6m market cap). Reported Earnings • May 15
Third quarter 2025 earnings released: US$0.94 loss per share (vs US$1.01 loss in 3Q 2024) Third quarter 2025 results: US$0.94 loss per share. Net loss: US$6.15m (loss widened 16% from 3Q 2024). New Risk • Apr 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$2.9m). Shareholders have been substantially diluted in the past year (49% increase in shares outstanding). Revenue is less than US$1m (US$678k revenue). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (US$37.3m market cap). Aankondiging • Apr 10
Pluri Inc. Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel Pluri Inc. announced that the U.S. Patent and Trademark Office has issued a patent covering the Company's immune cell expansion technologies. This patent specifically includes MAIT cells, a unique subset of T cells that are crucial in helping the body fight infection and repair tissue. The granted patents titled "System and Methods For Immune Cells Expansion and Activation In Large Scale" focus on a system and method for culturing and/or activating immune cells in a large scale, within Pluri's proprietary 3D cell expansion bioreactors. Offering substantial potential benefits compared to conventional T cells, Pluri's MAIT cells are isolated from the human placenta, a source rich in highly potent allogeneic immune cells. These cells are potent effector cells, potentially targeting tumors through multiple mechanisms while expressing high levels of various chemokine receptors, which facilitate their migration directly to tumor sites. The tightly controlled and fully automated bioreactor system provides cells with the conditions they need in order to expand, enabling efficient expansion of immune cells at scale and quality. The company believe that this innovative approach ensures that the produced immune cells retain their integrity, functionality, and therapeutic efficacy, thus offering a potentially promising solution to meet the escalating demand for advanced cell-based therapies for immune disorders and neurodegenerative diseases. Aankondiging • Mar 20
Pluri Inc. announced that it has received $3.5 million in funding from Merchant Adventure Investment Advisors, LLC On March 19, 2025 Pluri Inc. closed the transaction. The company received the proceeds from a single investor pursuant to Regulation D. Aankondiging • Mar 17
Pluri Inc., Annual General Meeting, May 14, 2025 Pluri Inc., Annual General Meeting, May 14, 2025. Location: matam advanced technology park building no. 5, 3508409., haifa Israel New Risk • Feb 13
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 34% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$2.9m). Shareholders have been substantially diluted in the past year (34% increase in shares outstanding). Revenue is less than US$1m (US$678k revenue). Minor Risk Market cap is less than US$100m (US$30.6m market cap). Reported Earnings • Feb 12
Second quarter 2025 earnings released: US$0.53 loss per share (vs US$0.94 loss in 2Q 2024) Second quarter 2025 results: US$0.53 loss per share (improved from US$0.94 loss in 2Q 2024). Net loss: US$2.96m (loss narrowed 40% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings. Aankondiging • Nov 28
Pluri Receives Nasdaq Notification of Non-Compliance with Listing Rule 5550(B)(1) On November 25, 2024, Pluri Inc., received a deficiency letter, or the Nasdaq Letter, from the Listing Qualifications Department of The Nasdaq Stock Market LLC, or Nasdaq, notifying the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires the Company to maintain a minimum of $2,500,000 in stockholders' equity for continued listing on The Nasdaq Capital Market, or the Stockholders' Equity Requirement, nor is it in compliance with either of the alternative listing standards, market value of listed securities of at least $35 million or net income of $500,000 from continuing operations in the most recently completed fiscal year, or in two of the three most recently completed fiscal years. Pursuant to the Nasdaq Letter, the Company has 45 calendar days from the date of the Nasdaq Letter to submit a plan to regain compliance and the Company intends to submit such a plan during this period. If it accepts the plan, Nasdaq can grant an extension of up to 180 calendar days from the date of the Nasdaq Letter to evidence compliance. In the event the plan is not accepted by Nasdaq, or in the event the plan is accepted and the 180-day extension period granted but the Company fails to regain compliance within such plan period, the Company would have the right to a hearing before an independent panel. The hearing request would stay any suspension or delisting action pending the conclusion of the hearing process and the expiration of any additional extension period granted by the panel following the hearing. The Company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq. However, there can be no assurance that Nasdaq will grant the Company's request for an extension or that the Company will ultimately regain compliance with all applicable requirements for continued listing. Neither the Nasdaq Letter nor the Company's noncompliance have an immediate effect on the listing or trading of the Company's common shares, which will continue to trade on The Nasdaq Capital Market under the symbol PLUR". Reported Earnings • Nov 14
First quarter 2025 earnings released: US$1.08 loss per share (vs US$0.96 loss in 1Q 2024) First quarter 2025 results: US$1.08 loss per share (further deteriorated from US$0.96 loss in 1Q 2024). Net loss: US$5.88m (loss widened 19% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings. New Risk • Nov 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (US$326k revenue). Minor Risks Share price has been volatile over the past 3 months (9.7% average weekly change). Shareholders have been diluted in the past year (5.8% increase in shares outstanding). Market cap is less than US$100m (US$24.9m market cap). Reported Earnings • Sep 20
Full year 2024 earnings released Full year 2024 results: Net loss: US$20.9m (loss narrowed 26% from FY 2023). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings. Aankondiging • Jul 24
Nasdaq Grants Extension Till Nov. 24 to Pluri Inc. to Regain Compliance with Stockholder Equity Requirement As previously reported, on May 28, 2024, Pluri Inc., or Pluri or the Company, received a deficiency letter, or the Nasdaq Letter, from the Listing Qualifications Department of The Nasdaq Stock Market LLC, or Nasdaq, notifying the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires the Company to maintain a minimum of $2,500,000 in stockholders' equity for continued listing on The Nasdaq Capital Market, or the Stockholders' Equity Requirement, nor is it in compliance with either of the alternative listing standards, market value of listed securities of at least $35 million or net income of $500,000 from continuing operations in the most recently completed fiscal year, or in two of the three most recently completed fiscal years. On July 11, 2024, the Company submitted a plan to regain compliance, or the Compliance Plan. Based on the Compliance Plan, Nasdaq has determined to grant the Company an extension of time to regain compliance with the Stockholders' Equity Requirement until November 24, 2024. If the Company fails to evidence compliance by the required deadline, the Company may be subject to delisting. At that time, the Company may appeal Staff's determination to a Hearings Panel. The Company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq. However, there can be no assurance the Company will ultimately regain compliance with all applicable requirements for continued listing. Neither the Nasdaq Letter nor the Company's noncompliance have an immediate effect on the listing or trading of the Company's common shares, which will continue to trade on The Nasdaq Capital Market under the symbol PLUR". Aankondiging • Jun 01
Pluri Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with Minimum of $2.5 Million in Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market On May 28, 2024, Pluri Inc. (Pluri or the Company) received a deficiency letter, or the Nasdaq Letter, from the Listing Qualifications Department of The Nasdaq Stock Market LLC, or Nasdaq, notifying the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires the Company to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on The Nasdaq Capital Market, or the Stockholders’ Equity Requirement, nor is it in compliance with either of the alternative listing standards, market value of listed securities of at least $35 million or net income of $500,000 from continuing operations in the most recently completed fiscal year, or in two of the three most recently completed fiscal years. Pursuant to the Nasdaq Letter, the Company has 45 calendar days from the date of the Nasdaq Letter to submit a plan to regain compliance and the Company intends to submit such a plan during this period. If it accepts the plan, Nasdaq can grant an extension of up to 180 calendar days from the date of the Nasdaq Letter to evidence compliance. In the event the plan is not accepted by Nasdaq, or in the event the plan is accepted and the 180-day extension period granted but the Company fails to regain compliance within such plan period, the Company would have the right to a hearing before an independent panel. The hearing request would stay any suspension or delisting action pending the conclusion of the hearing process and the expiration of any additional extension period granted by the panel following the hearing. The Company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq. However, there can be no assurance that Nasdaq will grant the Company’s request for an extension or that the Company will ultimately regain compliance with all applicable requirements for continued listing. Neither the Nasdaq Letter nor the Company’s noncompliance have an immediate effect on the listing or trading of the Company’s common shares, which will continue to trade on The Nasdaq Capital Market under the symbol ‘PLUR’. Reported Earnings • May 12
Third quarter 2024 earnings released: US$1.01 loss per share (vs US$1.53 loss in 3Q 2023) Third quarter 2024 results: US$1.01 loss per share (improved from US$1.53 loss in 3Q 2023). Net loss: US$5.29m (loss narrowed 31% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings. New Risk • Apr 02
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (US$357k revenue). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (US$31.0m market cap). Aankondiging • Mar 11
Pluri Inc. Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation Pluri Inc. announced an important expansion to its intellectual property portfolio with a new patent approval, that is designed to reshape the agricultural technology landscape. The patent titled "A System for 3D Cultivation of Plant Cells and Methods of Use" represents a major breakthrough in Pluri's proprietary 3D bioreactor technology, enabling efficient cultivation of plant cells across various applications, from sustainable agriculture to critical healthcare solutions. An immediate application for the patent is PluriAgtech’s sustainable cell-based coffee. The 3D cell expansion technology can produce high-quality coffee with 98% less water and 95% less growing area. Pluri’s patent and 3D cell expansion technology can also potentially address an emerging gap in agricultural healthcare, as approximately one-fifth of the 50,000 medical plants used on a list of threatened species. Aankondiging • Mar 06
Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board Pluri Inc. announced the appointment of attorney James Roosevelt, Jr. to the Company’s Advisory Board. Having served in public-service positions in Washington, D.C., followed by a successful decade in the private sector as CEO of Tufts Health Plan, Mr. Roosevelt is a trusted and sought-after advisor on business matters, legislative and regulatory issues, governance, and personnel matters. The intersection of public policy and health is a passion for him. As CEO of Tufts Health Plan, his leadership achieved consistent profitability while attaining the #1 ranking from the National Committee for Quality Assurance. Bringing his expertise to Pluri'sAdvisory Board, Mr. Roosevelt will contribute to the Company's strategic growth plans, particularly in the area of regenerative medicine, by advising on longevity opportunities, best practices for securing and maintaining ongoing grants and contracts with U.S. government agencies, and facilitating relationships with investors and partners. Before joining Tufts Health Plan, Mr. Roosevelt served as associate commissioner of the U.S. Social Security Administration and is a national speaker and published author writing about the Affordable Care Act, Medicare and Medicaid policy, and Social Security. He has also been a visiting fellow at the Institute of Politics of the Harvard Kennedy School of Government and continues as a clinical instructor in the Public Health and Community Medicine Department of Tufts University School of Medicine. In the tradition of his grandfather and other members of the Roosevelt family, Mr. Roosevelt co-chairs the Rules and Bylaws Committee of the Democratic National Committee and serves as volunteer legal counsel for the Massachusetts Democratic Party. Mr. Roosevelt is also a trustee of the Cambridge Public Library, the Cambridge Community Foundation, and the Atrius Health Equity Foundation. In the past, he has co-chaired Rhode Island Governor Gina Raimondo'sHealth-Care Leaders Task Force on Health-Care Cost Growth and the Massachusetts Hospital Association's work group on access to behavioral health care. Aankondiging • Feb 14
Pluri Inc. has filed a Follow-on Equity Offering in the amount of $10 million. Pluri Inc. has filed a Follow-on Equity Offering in the amount of $10 million.
Security Name: Common Shares
Security Type: Common Stock
Transaction Features: At the Market Offering Reported Earnings • Feb 14
Second quarter 2024 earnings released: US$0.12 loss per share (vs US$0.24 loss in 2Q 2023) Second quarter 2024 results: US$0.12 loss per share (improved from US$0.24 loss in 2Q 2023). Net loss: US$4.91m (loss narrowed 40% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings. Aankondiging • Jan 23
Pluri Inc. Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis Pluri Inc. announced that it has launched its cell-based coffee business activity, an innovative product that will potentially revolutionize the traditional coffee industry. Pluri’s cell-based coffee product is designed to address the growing global demand for sustainable, high-quality coffee at mass scale production. Pluri is pioneering plant cell-based, industrial scale manufacturing solutions for the coffee industry, leveraging its 3D cell expansion technology to create high quality coffee under the Company’s new business vertical, PluriAgtech. PluriAgtech aims to forge a brighter, greener future for agriculture by using breakthrough cell technology to create more eco-friendly alternatives to traditional farming methods. PluriAgtech’s cell-based coffee has been developed to deliver authentic coffee while solving key challenges faced by the industry. Compared to traditional methods of coffee production, Pluri’s cell-based coffee is estimated to slash water usage by 98%. This innovation promises to confront the reduction of suitable growing areas that are expected to decline by up to 50% by 2050; reduce price instability in a traditional commodity market; and minimize the environmental impact of coffee production, as current production methods have a high carbon footprint and upcoming regulations are expected to further strain producers. While coffee production challenges persist, world demand for coffee is expected to triple by 2050. Aankondiging • Jan 08
Pluri Inc. Appoints Andy Lewin to Lead Business of its Contract Development and Manufacturing Organization: PluriCDMO Division Pluri Inc. announced that it has appointed industry expert, Andy Lewin, to lead the business of its Contract Development and Manufacturing Organization (CDMO): PluriCDMO division. Mr. Lewin brings 25 years of commercial leadership experience within the CDMO sector in global companies including Ascend Gene and Cell Therapies Ltd., Oxford Biomedica, and AGC Biologics Inc. Reported Earnings • Nov 16
First quarter 2024 earnings released: US$0.12 loss per share (vs US$0.19 loss in 1Q 2023) First quarter 2024 results: US$0.12 loss per share (improved from US$0.19 loss in 1Q 2023). Net loss: US$4.96m (loss narrowed 19% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings. Aankondiging • Oct 20
Pluri Receives an Extension of an Additional 180 Calendar Days from The Nasdaq Stock Market LLC to Regain Compliance with the Minimum Bid Price Requirement On October 17, 2023, Pluri Inc. (the ‘Company’) received a letter (the ‘Letter’), from the Listing Qualifications Department (the ‘Staff’) of The Nasdaq Stock Market LLC (‘Nasdaq’) approving an extension of an additional 180 calendar days from the date of the Letter, or until April 15, 2024 (the ‘Additional Compliance Period’) to regain compliance with the Minimum Bid Price Requirement as well as approving the Company’s application to transfer its securities from the Nasdaq Global Market to The Nasdaq Capital Market starting at the opening of business on October 19, 2023. The Company’s Common Shares will continue to trade under the symbol ‘PLUR.’ The Nasdaq Capital Market is a continuous trading market that operates in substantially the same manner as The Nasdaq Global Market and listed companies must meet certain financial requirements and comply with Nasdaq’s corporate governance requirements. As previously disclosed, on April 19, 2023, the company received a written notification (the ‘Notice’) from the Staff of The Nasdaq Stock Market LLC, notifying the Company that for 30 consecutive trading days preceding the date of the Notice, the bid price of the Company’s common shares, par value $0.00001 per share (the ‘Common Shares’), had closed below the $1.00 per share minimum required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the ‘Minimum Bid Price Requirement’). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was granted 180 calendar days, or until October 16, 2023, to regain compliance with the Minimum Bid Price Requirement. If at any time during the Additional Compliance Period, the bid price of the Common Shares closes at or above $1.00 per share for a minimum of ten (10) consecutive trading days, Nasdaq will provide the Company with written confirmation of compliance with the Minimum Bid Price Requirement and the matter will be closed. If the Company does not regain compliance within the Additional Compliance Period or does not comply with the terms of the extension, Nasdaq will provide notice that the Company’s securities will be delisted from The Nasdaq Capital Market. The Company intends to continuously monitor the closing bid price for its Common shares and is in the process of considering various measures to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement. However, there can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement, even if it maintains compliance with the other Nasdaq listing requirements. Reported Earnings • Sep 13
Full year 2023 earnings released: US$0.77 loss per share (vs US$1.28 loss in FY 2022) Full year 2023 results: US$0.77 loss per share (improved from US$1.28 loss in FY 2022). Net loss: US$28.3m (loss narrowed 31% from FY 2022). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 60% per year, which means it is significantly lagging earnings. Aankondiging • Aug 17
Pluri Inc. Announces PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in Phase I Study: Results Published in Nature Bone Marrow Transplantation Pluri Inc. announced the publication of an article titled Placental expanded mesenchymal-like cells (PLX-R18) for poor graft function after hematopoietic cell transplantation: A phaseI study in the peer reviewed journal Nature Bone Marrow Transplantation. As described in the article, in a successful Phase I first-in-human study which achieved its primary endpoint, patients with incomplete hematopoietic recovery post-hematopoietic cell transplantation (HCT) were treated with escalating doses of Pluri’s cell therapy, PLX-R18. While patients received only two administrations of PLX-R18 during the first week, as compared to the standard of care which requires frequent and ongoing dosing, treated patients showed increased blood cell counts for as long as 12 months from administration, and a reduction in the need for blood transfusions. PLX-R18 was well tolerated with a favorable safety profile. PLX-R18, a placental-derived cell therapy, has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of graft failure, incomplete hematopoietic recovery following HCT, and the treatment of ARS. Low levels of blood cells (cytopenia) post-HCT can persist despite adequate engraftment of donor cells. Pluri’s PLX-R18 cells secrete a large array of hematopoietic factors which promote regeneration, maturation, and differentiation of hematopoietic cells and stimulate their migration to peripheral blood. Aankondiging • Jul 13
Pluri Inc. Announces Appointment of Lorne Abony to Board of Directors Pluri Inc. announced the appointment of Lorne Abony to the Company’s Board of Directors, effective as of July 11, 2023. Abony is a successful entrepreneur who has decades of experience building and scaling multi-billion-dollar global businesses – both public and private companies – across multiple industries. He is a globally recognized leader who has invested, directly or indirectly, in more than 20 cellular agriculture and cultivated food companies. Bringing his expertise to Pluri's board, he will contribute to the Company's strategic growth plans by utilizing its cell-expansion technology platform across various sectors, such as cultivated food and cellular agriculture. As a founder and executive, Mr. Abony has scaled major ventures including FUN Technology Ltd, Emmac Life Sciences Limited and NuuVera Inc. He has raised over $1.7 billion through public and private debt and equity markets. In 2011, Mr. Abony received Canada’s Ernst & Young Entrepreneur of the Year Award for his founding and leadership of Mood Media Corporation (Mood). Mr. Abony scaled Mood from a pre-revenue startup to the world’s largest in-store media company with more than 3,300 employees, offices in 47 countries and over $750 million in annual revenue, before selling the company to a private equity firm. He was also featured on the hit network T.V. series, “Undercover Boss.” Mr. Abony is currently chair and board member of several companies in the field of cultivated food, AI, and technology such as VitroLabs Inc., AmyInsights, and Einride A.B. Price Target Changed • Nov 16
Price target decreased to US$7.00 Down from US$9.75, the current price target is an average from 2 analysts. New target price is 757% above last closing price of US$0.82. Stock is down 71% over the past year. The company is forecast to post a net loss per share of US$1.25 next year compared to a net loss per share of US$1.28 last year. Board Change • Nov 16
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. 1 highly experienced director. Chairman Zami Aberman is the most experienced director on the board, commencing their role in 2005. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Price Target Changed • Apr 27
Price target increased to US$9.75 Up from US$7.75, the current price target is provided by 1 analyst. New target price is 541% above last closing price of US$1.52. Stock is down 66% over the past year. The company is forecast to post a net loss per share of US$1.55 next year compared to a net loss per share of US$1.77 last year. Board Change • Apr 27
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Member of Strategic Advisory Board Yoram Palti was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Price Target Changed • Apr 18
Price target increased to US$9.75 Up from US$7.75, the current price target is provided by 1 analyst. New target price is 427% above last closing price of US$1.85. Stock is down 55% over the past year. The company is forecast to post a net loss per share of US$1.55 next year compared to a net loss per share of US$1.77 last year. Board Change • Apr 01
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Member of Strategic Advisory Board Yoram Palti was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Board Change • Mar 03
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Member of Strategic Advisory Board Yoram Palti was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Feb 18
Chairman recently bought US$145k worth of stock On the 10th of February, Zami Aberman bought around 81k shares on-market at roughly US$1.80 per share. This was the largest purchase by an insider in the last 3 months. This was Zami's only on-market trade for the last 12 months. Price Target Changed • Dec 08
Price target decreased to US$7.75 Down from US$8.88, the current price target is an average from 3 analysts. New target price is 223% above last closing price of US$2.40. Stock is down 79% over the past year. The company is forecast to post a net loss per share of US$1.75 next year compared to a net loss per share of US$1.77 last year. Executive Departure • Jun 09
Independent Director Isaac Braun has left the company On the 1st of June, Isaac Braun's tenure as Independent Director ended after 15.9 years in the role. As of March 2021, Isaac still personally held 61.48k shares (US$293k worth at the time). A total of 4 executives have left over the last 12 months. The current median tenure of the management team is 1.92 years, which is considered inexperienced in the Simply Wall St Risk Model. Recent Insider Transactions • May 29
Insider recently sold US$1.6m worth of stock On the 25th of May, Adi Wolf sold around 410k shares on-market at roughly US$3.86 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought US$11m more than they sold in the last 12 months. Recent Insider Transactions • May 05
Insider recently sold US$102k worth of stock On the 3rd of May, Adi Wolf sold around 24k shares on-market at roughly US$4.28 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought US$13m more than they sold in the last 12 months. Is New 90 Day High Low • Mar 04
New 90-day low: US$5.58 The company is down 48% from its price of US$10.67 on 03 December 2020. The American market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$66.09 per share. Analyst Estimate Surprise Post Earnings • Feb 10
Earnings beat expectations Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 48%. Price Target Changed • Dec 11
Price target lowered to US$8.50 Down from US$17.13, the current price target is an average from 4 analysts. The new target price is 37% above the current share price of US$6.22. As of last close, the stock is up 78% over the past year. Is New 90 Day High Low • Dec 08
New 90-day high: US$11.40 The company is up 15% from its price of US$9.94 on 08 September 2020. The American market is up 11% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Biotechs industry, which is up 18% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$64.46 per share. Recent Insider Transactions • Dec 03
Insider recently bought US$194k worth of stock On the 30th of November, Adi Wolf bought around 20k shares on-market at roughly US$9.70 per share. In the last 3 months, they made an even bigger purchase worth US$2.0m. Insiders have collectively bought US$13m more in shares than they have sold in the last 12 months. Analyst Estimate Surprise Post Earnings • Nov 08
Earnings beat expectations Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 47%. Over the next year, revenue is forecast to grow 45,517%, compared to a 309% growth forecast for the Biotechs industry in the US. Recent Insider Transactions • Oct 30
Insider recently bought US$184k worth of stock On the 29th of October, Adi Wolf bought around 20k shares on-market at roughly US$9.20 per share. In the last 3 months, they made an even bigger purchase worth US$2.0m. Insiders have collectively bought US$12m more in shares than they have sold in the last 12 months. Recent Insider Transactions • Sep 25
Insider recently bought US$97k worth of stock On the 23rd of September, Adi Wolf bought around 11k shares on-market at roughly US$9.04 per share. In the last 3 months, they made an even bigger purchase worth US$1.6m. Insiders have collectively bought US$9.7m more in shares than they have sold in the last 12 months.